{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:36:24Z","timestamp":1771979784968,"version":"3.50.1"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified Glasgow Prognostic Score (mGPS) and neutrophil-to-lymphocyte ratio (NLR) was assessed. From 77 patients included, 83.2% received at least one prior systemic therapy. Immune-related adverse events (irAE) occurred in 20 patients. A lower mGPS was associated with higher median overall survival (OS), and a lower Eastern Cooperative Oncology Group (ECOG), irAE and fewer metastatic sites with better survival. A trend towards greater OS and progression-free survival (PFS) was stated among patients with NLR &lt;5. mGPS 0 was associated with better survival; \u22653 metastatic sites with worse PFS and OS; ECOG &gt;2 with worse OS and irAE with better survival. Pretreatment mGPS seems to be useful for predicting survival among advanced NSCLC patients treated with anti-programmed cell death 1 drugs, with ECOG performance status, irAE occurrence, and number of metastatic sites acting as survival predictors.<\/jats:p>","DOI":"10.1097\/cad.0000000000001060","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T16:28:54Z","timestamp":1614875334000},"page":"567-574","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents"],"prefix":"10.1097","volume":"32","author":[{"given":"Cl\u00e1udia","family":"Freitas","sequence":"first","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"},{"name":"Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro"}]},{"given":"Maria","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"}]},{"given":"Nuno","family":"Tavares","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"}]},{"given":"Nat\u00e1lia","family":"Cruz-Martins","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"},{"name":"Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro"},{"name":"Metabolism, Nutrition and Endocrinology, Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen"},{"name":"Laboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto"}]},{"given":"Concei\u00e7\u00e3o","family":"Souto-Moura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"David","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"}]},{"given":"H\u00e9lder","family":"Novais-Bastos","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"},{"name":"Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro"},{"name":"Metabolism, Nutrition and Endocrinology, Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen"}]},{"given":"Vanessa","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"}]},{"given":"Gabriela","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"},{"name":"Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro"}]},{"given":"Adriana","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"}]},{"given":"Venceslau","family":"Hespanhol","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"},{"name":"Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro"}]},{"given":"Henrique","family":"Queiroga","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Centro Hospitalar e Universit\u00e1rio S\u00e3o Jo\u00e3o"},{"name":"Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro"}]}],"member":"276","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"R1-20250617","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250617","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20250617","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20250617","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R5-20250617","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250617","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2016.07.028","article-title":"Checkpoint inhibitors in lung cancer are not immune from cost-effectiveness analysis.","volume":"11","author":"Kelly","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R7-20250617","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20250617","doi-asserted-by":"crossref","first-page":"376","DOI":"10.21037\/atm.2017.06.48","article-title":"Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.","volume":"5","author":"Voong","year":"2017","journal-title":"Ann Transl Med"},{"key":"R9-20250617","first-page":"5857","article-title":"Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab.","volume":"37","author":"Taniguchi","year":"2017","journal-title":"Anticancer Res"},{"key":"R10-20250617","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R11-20250617","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","article-title":"An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.","volume":"104","author":"Proctor","year":"2011","journal-title":"Br J Cancer"},{"key":"R12-20250617","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.amjsurg.2010.01.030","article-title":"Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma.","volume":"201","author":"Nozoe","year":"2011","journal-title":"Am J Surg"},{"key":"R13-20250617","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/0970-1591.124203","article-title":"External validation of the modified Glasgow prognostic score for renal cancer.","volume":"30","author":"Tai","year":"2014","journal-title":"Indian J Urol"},{"key":"R14-20250617","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.lungcan.2017.04.015","article-title":"Corrigendum to \u201cPrognosis in advanced lung cancer - a prospective study examining key clinicopathological factors\u201d [Lung Cancer 88 (2015) 304-309].","volume":"108","author":"Simmons","year":"2017","journal-title":"Lung Cancer"},{"key":"R15-20250617","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"R16-20250617","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"R17-20250617","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdu569","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.","volume":"26","author":"van Soest","year":"2015","journal-title":"Ann Oncol"},{"key":"R18-20250617","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/JTO.0000000000000399","article-title":"Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.","volume":"10","author":"Cannon","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R19-20250617","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bjc.2014.317","article-title":"The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer.","volume":"111","author":"Kang","year":"2014","journal-title":"Br J Cancer"},{"key":"R20-20250617","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2015.180","article-title":"Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.","volume":"112","author":"Ferrucci","year":"2015","journal-title":"Br J Cancer"},{"key":"R22-20250617","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R23-20250617","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"R24-20250617","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R25-20250617","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project.","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R26-20250617","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.","volume":"29","author":"DeNardo","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"R27-20250617","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis.","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"R28-20250617","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"R29-20250617","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer.","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"R30-20250617","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/sj.bjc.6603150","article-title":"An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer.","volume":"94","author":"Crumley","year":"2006","journal-title":"Br J Cancer"},{"key":"R31-20250617","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bjc.6602406","article-title":"The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder.","volume":"92","author":"Hilmy","year":"2005","journal-title":"Br J Cancer"},{"key":"R32-20250617","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjc.6602305","article-title":"Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas.","volume":"92","author":"Jamieson","year":"2005","journal-title":"Br J Cancer"},{"key":"R33-20250617","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/cncr.22896","article-title":"C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.","volume":"110","author":"Karakiewicz","year":"2007","journal-title":"Cancer"},{"key":"R34-20250617","first-page":"3001","article-title":"Preoperative serum C-reactive protein level in non-small cell lung cancer.","volume":"27","author":"Hara","year":"2007","journal-title":"Anticancer Res"},{"key":"R35-20250617","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2407-10-50","article-title":"Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.","volume":"10","author":"Arrieta","year":"2010","journal-title":"BMC Cancer"},{"key":"R36-20250617","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0169-5002(95)00407-R","article-title":"Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer.","volume":"12","author":"Espinosa","year":"1995","journal-title":"Lung Cancer"},{"key":"R37-20250617","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S0029665108007131","article-title":"An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.","volume":"67","author":"McMillan","year":"2008","journal-title":"Proc Nutr Soc"},{"key":"R38-20250617","doi-asserted-by":"crossref","first-page":"e0184412","DOI":"10.1371\/journal.pone.0184412","article-title":"Clinical utility of the modified Glasgow prognostic score in lung cancer: a meta-analysis.","volume":"12","author":"Jin","year":"2017","journal-title":"PLoS One"},{"key":"R39-20250617","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/JTO.0b013e318244ffe1","article-title":"Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.","volume":"7","author":"Leung","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R40-20250617","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.12659\/MSM.903710","article-title":"Modified glasgow prognostic score at recurrence predicts poor survival in resected non-small cell lung cancer (NSCLC) patients.","volume":"23","author":"Lv","year":"2017","journal-title":"Med Sci Monit"},{"key":"R41-20250617","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s13277-014-2623-4","article-title":"A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer.","volume":"36","author":"Zhou","year":"2015","journal-title":"Tumour Biol"},{"key":"R42-20250617","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3892\/mco.2017.1261","article-title":"Modified glasgow prognostic score in patients with small-cell lung cancer.","volume":"7","author":"Kurishima","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"R43-20250617","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijrobp.2015.02.018","article-title":"Pretreatment modified glasgow prognostic score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.","volume":"92","author":"Kishi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R44-20250617","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.21873\/anticanres.13262","article-title":"Post-treatment glasgow prognostic score predicts efficacy in advanced non-small-cell lung cancer treated with anti-PD1.","volume":"39","author":"Kasahara","year":"2019","journal-title":"Anticancer Res"},{"key":"R45-20250617","doi-asserted-by":"crossref","first-page":"1520-1528","DOI":"10.21037\/jtd.2020.02.27","article-title":"The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.","volume":"12","author":"Matsubara","year":"2020","journal-title":"J Thorac Dis"},{"key":"R46-20250617","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion.","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"R47-20250617","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cllc.2018.04.021","article-title":"Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non\u2013small-cell lung cancer: a prospective observational study.","volume":"20","author":"Fukui","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R48-20250617","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"R49-20250617","doi-asserted-by":"crossref","first-page":"404","DOI":"10.21037\/tlcr.2018.04.03","article-title":"Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience.","volume":"7","author":"Manrique","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R50-20250617","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s12094-017-1829-5","article-title":"Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.","volume":"20","author":"Garde-Noguera","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"R51-20250617","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.11.015","article-title":"Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data.","volume":"126","author":"Dudnik","year":"2018","journal-title":"Lung Cancer"},{"key":"R52-20250617","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pulmoe.2019.06.001","article-title":"Real-world data from the portuguese nivolumab expanded access program (EAP) in previously treated non small cell lung cancer (NSCLC).","volume":"26","author":"Figueiredo","year":"2020","journal-title":"Pulmonology"},{"key":"R53-20250617","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials.","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R54-20250617","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression.","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R55-20250617","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes.","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R56-20250617","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study.","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R57-20250617","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"R58-20250617","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer.","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"R59-20250617","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non\u2013small cell lung cancer patients treated with nivolumab: a prospective cohort study.","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R60-20250617","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients.","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R61-20250617","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4143\/crt.2013.45.2.95","article-title":"Predicting survival in patients with advanced non-squamous non-small cell lung cancer: validating the extent of metastasis.","volume":"45","author":"Lee","year":"2013","journal-title":"Cancer Res Treat"},{"key":"R62-20250617","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12032-018-1182-8","article-title":"Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.","volume":"35","author":"Gibson","year":"2018","journal-title":"Med Oncol"},{"key":"R63-20250617","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ctrv.2013.10.001","article-title":"The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets.","volume":"40","author":"Wood","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R64-20250617","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/1097-0142(19900601)65:11<2426::AID-CNCR2820651104>3.0.CO;2-3","article-title":"Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.","volume":"65","author":"Joss","year":"1990","journal-title":"Cancer"},{"key":"R65-20250617","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1002\/cncr.24333","article-title":"Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases.","volume":"115","author":"Oh","year":"2009","journal-title":"Cancer"},{"key":"R66-20250617","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ijrobp.2009.12.060","article-title":"Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy.","volume":"79","author":"Alexander","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R67-20250617","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cllc.2012.10.007","article-title":"Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.","volume":"14","author":"Park","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"R68-20250617","first-page":"3643","article-title":"The genetic origin of drug resistance in neoplasms: implications for systemic therapy.","volume":"44","author":"Goldie","year":"1984","journal-title":"Cancer Res"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000001060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:04:44Z","timestamp":1750187084000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000001060","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}